After more than two years of pitching investors, a London upstart with two current employees has pulled through with a $33 million Series A to see if it can crack into a relatively niche pocket …
Tenaya targets $60M offering after heart disease pipeline updates
Tenaya Therapeutics, a company focused on developing gene therapies for heart conditions, made a series of announcements on Thursday. The biotech said the FDA has

